Education
About Us
Working with TipRanks
Follow Us
Springworks Therapeutics (SWTX)
:SWTX
SWTX Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Springworks Therapeutics News
SWTX FAQ
What was Springworks Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Springworks Therapeutics’s market cap?
Currently, no data Available
When is Springworks Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Springworks Therapeutics’s earnings last quarter?
Currently, no data Available
Is Springworks Therapeutics overvalued?
According to Wall Street analysts Springworks Therapeutics’s price is currently Undervalued.
Does Springworks Therapeutics pay dividends?
Springworks Therapeutics does not currently pay dividends.
What is Springworks Therapeutics’s EPS estimate?
Springworks Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Springworks Therapeutics have?
Currently, no data Available
What happened to Springworks Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Springworks Therapeutics?
Currently, no hedge funds are holding shares in SWTX
Company Description
Springworks Therapeutics
Springworks Therapeutics (SWTX) is a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company leverages its deep understanding of disease biology and innovative approaches to drug development to create targeted therapies. Its lead product candidates include nirogacestat and mirdametinib, which are in various stages of clinical trials for treating desmoid tumors and neurofibromatosis type 1, respectively.
Springworks Therapeutics (SWTX) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Ultragenyx Pharmaceutical
―
Protagonist Therapeutics
―
Crispr Therapeutics AG
―
Rhythm Pharmaceuticals
―
Akero Therapeutics
―
Ownership Overview
―
Insiders
18.09%
Mutual Funds
― Other Institutional Investors
81.47% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---